Loading
A phase 1/2 trial of Gecacitinib in non-small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06903377 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 50 participants planned, started 2025-05-23 and due to reach its primary completion in 2027-04. Interventions recorded: ZG005 for Injection and Gecacitinib Hydrochloride Tablets.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gecacitinib, Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/